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Abstract
Epithelial mesenchymal transition (EMT) is characterized by the development of mesenchymal properties such as a
fibroblast-like morphology with altered cytoskeletal organization and enhanced migratory potential. We report that the
expression of podocalyxin (PODXL), a member of the CD34 family, is markedly increased during TGF-b induced EMT. PODXL
is enriched on the leading edges of migrating A549 cells. Silencing of podocalyxin expression reduced cell ruffle formation,
spreading, migration and affected the expression patterns of several proteins that normally change during EMT (e.g.,
vimentin, E-cadherin). Cytoskeletion assembly in EMT was also found to be dependent on the production of podocalyin.
Compositional analysis of podocalyxin containing immunoprecipitates revealed that collagen type 1 was consistently
associated with these isolates. Collagen type 1 was also found to co-localize with podocalyxin on the leading edges of
migrating cells. The interactions with collagen may be a critical aspect of podocalyxin function. Podocalyxin is an important
regulator of the EMT like process as it regulates the loss of epithelial features and the acquisition of a motile phenotype.
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Introduction
Epithelial mesenchymal transition (EMT) is characterized by a
loss of the epithelial cell properties of apical basal polarity and tight
cell – cell adhesions. These are accompanied with the acquisition
of mesenchymal properties of anterior – posterior polarity,
migratory and invasive behaviors [1]. This transition is essential
during embryonic development, organogenesis, and wound repair.
However, EMT may also contribute to the tissue changes
observed in diseases such as tissue fibrosis, invasive cancer,
rheumatoid arthritis and some other diseases [1–7].
Many factors have subsequently been demonstrated to partic-
ipate in the EMT like behavior since the first inducer, hepatocyte
growth factor, was identified in 1985 [8]. These include growth
factors and their corresponding cell surface receptors [e.g.
transforming growth factor-b (TGF-b), epidermal growth factor
(EGF), fibroblast growth factor (FGF)]. Several transcription
factors (Snail, ZEB, Twist), and signaling molecules (Wnt, Notch,
NF-kB) also contribute to this process [9–12]. There has been
extensive research detailing of the molecular processes and
compositional changes associated with EMT as these could be of
value in monitoring in vivo its progression or providing a new
approach to regulating these transitions. The loss of E-cadherin
expression is a critical and fundamental event in EMT, and many
inducers of this process act directly or indirectly by repressing E-
cadherin expression [6,11,13–19]. Increased expression of vimen-
tin and alpha–smooth muscle actin is also associated with EMT in
specific cell context [20–22]. Although repression of E-cadherin
expression in EMT accounts for the loss of intercellular adhesion
and polarity, it is still unclear how the cells acquire the capacity of
migration [23–28].
We recently identified podocalyxin (PODXL) as a markedly up-
regulated protein in TGF-b induced EMT of human A549 cells.
PODXL is a type I transmembrane glycoprotein and a member of
the CD34 family. Similar to other members of this family it can be
extensively O-glycosylated and sialylated. Podocalyxin was
originally identified on podocytes in kidney where it is essential
for normal renal development [29]. It is also expressed by
hematopoietic progenitors, vascular endothelia, and a subset of
neurons. Podocalyxin has also been observed in subsets of breast,
prostate, liver, pancreatic and kidney cancer as well as leukemia
[30,31]. Elevated expression of podocalyxin in these cancers is
often associated with aggressive invasion and poor prognosis.
Podocalyxin has a number of interaction partners including Na+/
H+ exchanger regulatory factor (NHERF), the actin binding
protein ezrin, the adhesion molecule L-selectin, and cortac-
tin[20,32,33].
Podocalyxin is involved in the regulation of cell adhesion and
cell morphology with often seemingly opposing roles. It has an
anti-adhesive function in podocytes while it is a pro-adhesive
molecule in lymphocytes enhancing their adhesion to immobilized
L-selectin [34–37]. The latter properties may contribute to the
increased rate of cancer cell migration. It is unclear how
podocalyxin mediates these distinct effects in different cellular
contexts. One suggestion is that the levels of podocalyxin
expression may contribute to these apparently contradictory roles
in cell adhesion [31]. Low level podocalyxin could establish apical
domains and force integrins to the basal surface of cells, thereby
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strongly induce microvillus formation, depleting basolateral actin
and disrupting integrin mediated adhesion.
The present study was initiated to examine the role of
podocalyxin in TGF-b induced EMT. Podocalyxin was found to
play several roles in EMT like behavior. Its expression was
increased following TGF-b treatment and it was required for
migration of the transitioned cells. Podocalyxin was also shown to
bind and colocalize with secreted collagen type 1. It appears that
podocalyxin may play a role in the control of cell migration by
regulating the dynamics of cell protrusion formation and
interactions with collagen type 1.
Methods
Cells and Culture
The human lung adenocarcinoma cell line A549, human
embryonic kidney cell line 293T, and human breast cancer cell
line MDA-MB-231 were obtained from the American Type
Culture Collection (ATCC) (Manassas, VA) and maintained in
DMEM supplemented with 10% fetal bovine serum (FBS)
(Invitrogen). For induction of EMT, A549 cells were cultured in
10% FBS for 24 hour and then maintained for 72 hours in serum
free medium in the presence of 2 ng/ml of TGF-b (Millipore,
Billerica, MA).
Antibodies and reagents
The following antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA): mouse antibodies to human
GAPDH, Vimentin, E-cadherin; rabbit antibody to podocalyxin;
goatantibodytochain2ofcollagentype1.Ahorseradishperoxidase
(HRP) conjugated rabbit anti-mouse immunoglobulin was obtained
from Sigma-Aldrich (St. Louis, MO). Oregon green 488 labeled
phalloidin, cy3 labeled donkey anti-rabbit immunoglobulin, and
Oregon green 488 conjugated donkey anti-goat IgG were obtained
from Jackson ImmunoResearch (West Grove, PA). A mouse anti-
human serum albumen IgG was an in house produced reagent.
Western Blot
Total cell protein extracts were prepared by lysing cells in buffer
containing 100 mM Tris (pH 6.8), 2% SDS, 50 mM DTT and
20% glycerol. The samples were boiled, sonicated and protein
contents were estimated using the Pierce bicinchoninic acid assay
(Pierce Biotechnology, Rockford, IL). Proteins were separated by
electrophoresis on NovexH 4–12% Tris-Glycine gradient Gels
(Invitrogen) and transferred to nitrocellulose membranes using a
semi-dry transmembrane device (Bio-Rad, Missisauga, ON). The
membranes were probed overnight with primary antibody (1 mg/
ml) in PBS followed by incubation with the appropriate HRP
conjugated secondary antibody as indicated. Amersham ECL
Western Blotting reagent was used to develop the blots. The blot
intensity was measured by Quantity One software (Bio-Rad).
Immunoprecipitaton
A549 cells were cultured in four 10 cm dishes for 48 hours to
80% confluence. The media was removed and the dishes were
washed with PBS. A total of 250 ml lysis buffer containing 2%
Triton X-100 in 50 mM Tris (pH 7.4) 150 mM NaCl, was added
to each dish on ice. The cells were collected by scraping and
transferred to microfuge tubes. After incubation on ice for 30
minutes, the samples were briefly sonicated and centrifuged at
10,000 rpm for 10 min to remove insoluble debris. The
supernatant was collected and aliquots were incubated for 2 hours
at 4uC with protein-G Dynal beads pre-coated with 5 mgo f
monoclonal antibody to either podocalyxin or human serum
albumin (HSA). The beads were washed 4 times with lysis buffer
and the immunoprecipitates were digested on the beads with
trypsin (5 mg/ml) in 100 mM NH4HCO3. The resulting peptides
were analysed by mass spectrometry.
shRNAmir interference
Three lentiviral clones containing shRNA-mir against podoca-
lyxin (catalog number: RHS3979-98487906, RHS3979-98487914,
and RHS3979-98487921) were purchased from Open Biosystems.
Lentiviral particles were packaged with vector psPAX2 and vector
pMD2.G according to the supplier’s instruction (Open Biosystems,
Huntsville, AL). A control virus lacking a shRNA insert was used in
parallel experiments as control. Virus containing supernatants were
transferred to A549 cells at 60% confluence and incubated for
6 hours. Fresh media was added to the cultures and the cells were
incubated for 24 hours after which puromycin (5 ng/ml) was added
to the cultures to select transduced cells. Puromycin resistant cells
were examined for podocalyxin expression. The cells tranduced
with shRNA-mir clone RHS3979-98487914 or RHS3979-
98487921 produced markedly lower podocalyxin by western blot
examination and appeared in obviously changed morphology. A
mixed population of puromycin resistant cells from clone
RHS3979-98487921 were maintained in media containing puro-
mycin and used in all the experiments. A rescue test was not
performed for further demonstration of the specificity.
Cell migration assay
Transwells (8 mm pore size, 6.5 mm, Corning) were coated with
gelatin (0.1%) overnight at 4uC. Cells (2610
5/well) in media
containing 0.5% serum were added into the inserts and placed in
wells containing the same medium plus TGF-b (5 ng/ml) as
chemotactic factor. The cells were cultured for 2 to 4 hours and
then fixed with either 3.8% paraformaldehyde for immunofluore-
cence or 30% methanol plus 0.5% crystal violet for quantitation of
cell number. The cells remaining on the upper surface of the filter
were removed with a cotton swab and the numbers of migrating
cells in three high power fields of the lower surfaces of the
membranes were counted. A minimum of three wells were
counted per experiment.
Wound healing assay
Confluent cultures of control and silenced A549 cells were
maintained in the presence of TGF-b for 48 hours. The
monolayers were then scratched with a 200 ml pipette tip and
washed to remove the detached cells. The wounded areas were
then imaged after incubation for an additional 16 hours in media
without TGF-b.
Immunofluorescence
Cells on chamber slides or transwell filters were fixed with 3.8%
paraformaldehyde for 30 min and permeablized with 0.2% triton
X-100 for 1 min. The cells were then treated sequentially with the
indicated primary antibodies in PBS followed by 3 washes in PBS
and subsequent incubation with appropriate fluorescent secondary
antibody conjugates. Each of the incubations with antibody was
for 30 minutes. Images were collected on a Zeiss Axio Observer
microscope with Axio Vision software.
Results
TGF-b induced EMT and podocalyxin expression
Several features of TGF-b treated cells were examined to
confirm that EMT like properties were induced under our culture
Podocalyxin Participates in EMT
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compositional changes consistent with EMT following treatment
with TGF-b [23,38]. These included the loss of apical polarity
with the acquisition of a more fibroblast like spindle shape and
cytoskeletal remodeling with the appearance of actin stress fibers
(Fig. 1). There was also a loss of expression of the epithelial
marker, E-cadherin, and a concomitant increase of the mesen-
chymal marker, vimentin.
In preliminary proteomic studies we observed that PODXL
levels increased in A549 cells following TGF-b treatment. The
kinetics of these changes was examined by western blot analysis of
PODXL levels. There was a modest increase in PODXL following
24 hours treatment. These reached plateau levels following
72 hours treatment and were maintained for at least 120 hours
which was the longest time point examined (Fig. 2). The maximal
PODXL expression levels at day 3 were approximately 5 times
those of control basal. The changes in PODXL expression
appeared to precede the development of fibroblast like morpho-
logical features as the former were detectable after 24 h of
treatment while the latter were only apparent after at least
48 hours of culture with TGF-b [23,39].
Podocalyxin is required for cell migration
A characteristic feature of EMT is the acquisition of an invasive
migratory phenotype. We questioned whether podocalyxin
participated in cell migration in this specific situation. To examine
this possibility, we established podocalyxin knock down cell lines
(PODXL-KD) using lentiviral vector based shRNAmir silencing.
Figure 1. TGF-b induced EMT. A549 cells were cultured in medium
without (A, C) or with TGF-b (2 ng/ml) (B, D) for 3 days. Cellular
morphology (A, B) was photographed by phase contrast microscope.
Actin cytoskeleton (C, D) was visualized by Oregon green 488
conjugated phalloidin staining and photographed by fluorescence
microscope. Scale bar=50 mm. The effects of TGF-b on expressions of
EMT markers, E-cadherin and vimentin, were examined by western blot.
GAPDH from the same loading was used as control.
doi:10.1371/journal.pone.0018715.g001
Figure 2. Induction of podocalyxin by TGF-b. A549 cells were
incubated with TGF-b (2 ng/ml) for the indicated times and the cells
were collected for western blot. The blots were established by mouse
anti-podocalyxin and HRP-conjugated rabbit anti-mouse secondary
antibody. GAPDH was also monitored on the same filter as control.
doi:10.1371/journal.pone.0018715.g002
Figure 3. Effects of podocalyxin silence on cell morphology
and podocalyxin production. A): Podocalyxin shRNA transduced
cells (PODXL-KD) (lane 2,4,6,8) and control A549 cells (transduced with
the same vector without shRNA insert) (lane 1,3,5,7) were cultured in
the presence or absence of TGF-b for 1 to 3 days. Podocalyxin levels
were examined by western blot. GAPDH were also determined as
loading controls. B): Cell morphology under phase contrast microscope
before and after silencing podocalyxin. Scale bar=50 mm.
doi:10.1371/journal.pone.0018715.g003
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reduced to ,15% of that of control basal levels (Fig. 3A).
Following treatment with TGF- b podocalyxin production was
increased in PODXL-KD cells but remained at less than 20% of
the control cells at all time points (Fig. 3A, compare even and odd
lanes at each time point). The PODXL-KD cells became more
epithelial in morphology with the formation of tight cell clusters
and a reduction in the number of cell protrusions (Fig. 3B).
Untreated control A549 cells display a low capacity of
chemotaxis in response to TGF-b (panel A of Fig. 4). This
response was further reduced in PODXL-KD cells (compare
columns 1, 2 of Fig. 4A). Pretreatment of control A549 cells with
TGF-b for 72 hours induced a marked increase in their
chemotactic responses. Although the migration of PODXL-KD
cells were also increased by this treatment, they never exceeded
,30% of treated control A549 cells (column 3, 4). It was notable
that there were obvious differences in the morphologies between
transmigrated PODXL-KD and control cells (panel B of Fig. 4).
TGF-b treated A549 cells passed through the filter and extended
large cell projections on the lower membrane surface (C of panel
B). In contrast, TGF-b treated PODXL-KD cells entered the
membrane pores but very few penetrated and extended to the
lower membrane surface (D of panel B).
The migratory capacities of TGF-b treated A549 and PODXL-
KD cells were also measured using an in vitro wound repair assay
(panel C of Fig. 4). Many TGF-b treated A549 cells migrated into
the wound area within 18 hour of wound recovery. These cells
exhibited motile shapes with clearly polarized fronts and
extensions into the wound area (B of panel C). The situation in
the PODXL-KD cells was quite different (C of panel C). There
was little evidence of individual cells entering into the wound
space. However, the narrowing of the wound space suggests that
the cells would eventually close the wound. This could potentially
be caused by cell propagation. Collectively these results suggested
that podocalyxin is required for TGF-b induced cell migration.
Podocalyxin levels influence the expression of molecular
markers of EMT
The loss of E-cadherin is typically associated with an increase in
vimentin expression during EMT. These events are thought to
contribute to acquisition of the cellular phenotypic changes
associated with the transition. It was therefore questioned whether
podocalyxin played any role in regulating these changes.
A549 and PODXL-KD cells were treated with TGF-b for 1 to 3
days and the levels of E-cadherin and vimentin were measured by
western blot (Fig. 5). The basal levels of E-cadherin and vimentin
were unaffected by podocalyxin silencing despite the clear
differences in cellular morphology. Treatment of control cells
with TGF-b resulted in the loss of E-cadherin by 48 hours of
culture. This was associated with a concomitant increase in
vimentin which was most notable by 72 h of culture. However the
situation was very different when PODXL-KD cells were treated
in a similar fashion. E-cadherin never fully disappeared in
PODXL-KD cells following TGF-b treatment. Very modest
increases in vimentin were detected from day 2 in PODXL-KD
cells. These results suggest that podocalyxin may contribute to the
regulation of the molecular changes associated with EMT.
Podocalyxin affects cell spreading and enriches at the
leading edge of migrating cells
As indicated by the results of the previous sections that PODXL
plays a role in TGF-b induced EMT and chemotaxis, we
examined the expression and distribution of podocalyxin on
Figure 4. Podocalyxin is involved in TGF-b induced cell migration. A) A549 (column 1, 3) and PODXL-KD (column 2,4) cells were cultured for
3 days in medium containing 0.5% serum without (column A,B) or with (column C,D) TGF-b (2 ng/ml). The migration capacities of these cells in
response to TGF-b (5 ng/ml) were measured on gelatin coated transwells. The cells were cultured for 4 hours and fixed with methanol containing
0.5% crystal violet. The numbers of cells per 206magnified lens field were counted (panel A). Three fields per transwell were counted in triplicate
experiments. The mean values with standard deviations are indicated on top of each column with a student T test analysis p,0.01 (*). B) The
morphology of cells that migrated to the lower surface of transwell filters. Images A–D correspond the cells of column 1–4 in panel A. C) Wound
recovery assay. A549 and PODXL-KD cells were cultured for 48 hours in the presence of TGF-b (2 ng/ml) and were scratched with pipette tip (A). The
cells were washed and cultured in medium without TGF-b for 16 hours. The images of cell recovery were taken under phase contrast microscope.
A549 (B) and PODXL-KD (C).
doi:10.1371/journal.pone.0018715.g004
Figure 5. Podocalyxin is required for TGF-b induced EMT marker expressions. A549 and PODXL-KD cells were treated with TGF-b for 1–3
days, and monitored by western blot for their expressions of podocalyxin, E-cadherin and vimentin. TGF-b up-regulated the production of
podocalyxin and vimentin in A549 cells, and down-regulated E-cadherin level to zero in a time dependent manner. Silencing of podocalyxin
interfered with TGF-b mediated down-regulation of E-cadherin and up-regulation of vimentin.
doi:10.1371/journal.pone.0018715.g005
Podocalyxin Participates in EMT
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treatment. Podocalyxin appeared in a relatively even and diffuse
pattern on un-treated control cells and enriched on ruffle like
leading edges of spreading cells (Fig. 6 Arrows in column of A549).
Knocking down podocalyxin not only resulted in clear deduction
of podocalyxin intensity, but also made the cell smaller and lack
protrusions. The cells became aggregated with very few separated
single cell in the culture. As E-cadherin was not increased in
podocalyxin silenced cells, we deduced that the aggregating
pattern was caused by damaged spreading and migrating
capacities but not through enhancing cell-cell adhesions. The
average number of ruffle with podocalyxin enrichment on A549
cells was 51 based on percentage counting, while only 9 of that
were observed on PODXL-KD cells (data not shown). Following
TGF-b treatment, the A549 cell changed to a larger spreading
shape (2–4 fold in size) with obvious increase in podocalyxin
expression and cytoskeleton assembly. The number of ruffle
structure markedly decreased in TGF-b treated cells, which could
be explained by lacking chemotactic factor gradients, as these cells
showed very actively migratory capacities in transwell system.
TGF-b slightly enhanced podocalyxin production in PODXL-KD
cells and its spreading, but that had never reached the levels of
control cells.
To better determine the distribution of podocalyxin on
migrating cells, we treated cells with TGF-b for 72 hours and
then induced chemotaxis in transwells against TGF-b. The cells
were then fixed and stained for podocalyxin and F actin (Fig. 7).
TGF-b induced cells that had passed through the pores of the
transwell showed marked podocalyxin enrichment along with F-
actin at the leading edges (A-D). In contrast PODOXL-KD cells
had very few projections to the lower surface of the transwell (E–
H). The few projections observed were stained more intensely for
podocalyxin, suggesting that these cells had less inhibition of
podocalyxin than the bulk of the non migrating population of cells.
Podocalyxin associates with collagen type 1
An examination of potential PODXL interacting proteins was
initiated as an approach to understanding of the mechanism of
podocalyxin actions in regulating cell migration. Anti-podocalyxin
derived immunoprecipitates were isolated from A549 cells and
analyzed by mass spectrometry. The compositions of these
immunoprecipitates were compared with those obtained with a
control antibody to human serum albumin (HSA). This provided a
basis for identifying proteins that were nonspecifically isolated
during the immunoprecipitation process. The selection criteria for
candidate proteins were either two peptides matched or log10(e)
was less than 210, where the log(e) indicates the probability of a
random assignment of that confidence level (Table 1). Type I
collagen chains and podocalyxin were consistently identified in the
anti-podocalyxin immunoprecipitates of all three independent
experiments. In contrast other proteins such as keratins, vimentin,
plectin and actin were present in both of the podocalyxin and
control immunoprecipitates, suggesting that these proteins were
not specifically captured during the isolation process. These results
suggested that podocalyxin and collagen type 1 are associated with
one another in A549 cells.
Efforts to perform reciprocal immunoprecipitates with three
different antibodies to type 1 collagen consistently failed to isolate
either collagen or PODXL. Thus we examined the co-distribution
of podocalyxin and type 1 collagen alpha 2 chain as an indirect
indicator of possible association (Fig. 8). Podocalyxin and collagen
type 1 had very similar distribution patterns on A549 cells. There
was a marked enrichment and colocalization of collagen and
podocalyxin on the edges of cell extending projections. When
Figure 6. The distribution of podocalyxin. A549 and PODXL-KD were cultured in the presence or absence of TGF-b (2 ng/ml) for 3 days. The cells
were fixed with 3.8% paraformaldehyde and permeablized. The expression of podocalyxin (red) was visualized by applying primary rabbit anti-
podocalyxin antibody and cy3 conjugated goat anti-rabbit secondary antibody. F-actin was stained with Oregon green conjugated phalloidin. Images
of immunofluorescence and differential interference contrast (DIC) were taken for each field and merged. The blue color in the merged pictures
indicates nuclei stained by DAPI. Arrows indicated the ruffles of cell protrusions. Scale bar=50 mm.
doi:10.1371/journal.pone.0018715.g006
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transwells and then stained for PODXL and collagen, both
molecules were seen enriched and co- distributed on the leading
edges of projecting cells (Fig. 8).
The distributions of podocalyxin and collagen type 1 in the
highly metastatic breast cancer cells MDA-MB-231 were also
examined. The majority of these cell population had typical
migratory protrusions. In all cases a component of the podocalyxin
and collagen were colocalized in the protrusions. These observa-
tions suggest that podocalyxin and collagen type 1 interactions
may occur during cell migration.
Discussion
The possible role of EMT like behavior in metastatic cancer has
stimulated a number of investigations into the molecular events of
this process because information in this area may help to identify
new approaches to the treatment [10,21,23,27,40]. The results of
the present study provide several new pieces of information
regarding possible podocalyxin function(s) and the process of
EMT. These observations are particularly relevant given the
observation of podocalyxin on stem cells and cancer cells suggesting
potential commonalities in the cellular properties that are involved.
Our results demonstrate that the up regulation of podocalyxin is
necessary for epithelial mesenchymal transition. The inhibition of
podocalyxin expression prevented the TGF-b induced develop-
ment of an invasive migratory phenotype and the associated
morphological changes. Lowered level of podocalyxin affected
TGF-b induced E-cadherin deduction and vimentin increase. This
requirement for podocalyxin seemed to be related to responses to
TGF-b as the basal levels of vimentin and E-cadherin were
comparable in untreated control and PODOXL-KD cells. These
coordinated regulations are consistent with a recent report
indicating that in pluripotent stem cells podocalyxin interacted
with the glucose-3-transporter and the levels of both molecules
were coordinately regulated [41]. Collectively these results suggest
that podocalyxin is an important component of a regulatory
network in TGF-b induced EMT like behavior.
Podoclayxin appears to have an enigmatic role in cell adhesion
as it has been described to have both pro and anti adhesive roles
depending on cell types and the glycosylation pattern of the
molecule [31]. Over expression of podocalyxin in Madin-Darby
canine kidney (MDCK) and Chinese hamster ovary (CHO) cell
Table 1. Compositional analysis of Podocalyxin containing
immunoprecipitates.
IP of anti-HSA IP of anti-PODXL
Accession Protein ID MW(kDa) #pep log(e) #pep log(e)
P63261 Actin 41.8 7 274.9 7 268.8
P62807 Histone H2B/a 13.9 3 221.1 2 214.2
P04264 Keratin-1 66 12 2119.3 13 2114.8
P35908 Keratin-2 65.4 8 274.6 6 250.3
P08729 Keratin-7 51.4 3 222.4 12 282
P05787 Keratin-8 53.7 3 219.5 11 273.2
P35527 Keratin-9 62 7 262.7 5 235.9
P13645 Keratin-10 58.8 7 265.7 5 245.8
Q15149 Plectin-1 518.2 9 267.3 16 2135.2
P08670 Vimentin 53.6 45 2348.1 100 2525.5
Q13148 TDP-43 44.7 3 233.6
P62829 RPL-23 14.9 2 210.5
P02452 COL1A1 138.9 20 2165.9
P08123 COL1A2 129.2 6 248
O00592 Podocalyxin 58.6 5 228
#pep: number of peptides matched.
log(e): probability of mismatched.
doi:10.1371/journal.pone.0018715.t001
Figure 7. Podocalyxin enriched on the leading edges of migrating cells. A549 (A–D) and PODXL-KD (E–H) cells were pretreated with TGF-b
for 3 days and placed in transwell containing TGF-b (5 ng/ml) gradient for two hours. The cells on the filter were fixed with paraformaldehyde (3.8%)
and stained for podocalyxin (Cy3 red) and F-actin (Oregon green-488 Phalloidin, green). Both podocalyxin and F-actin enriched on the leading edges
of the migrating cells and colocalised each other as showed in merged photo (C). In contrast very few PODXL-KD cells were observed passing
through the pores under the same conditions. Bright fields combined images (D and H) were also provided to visualize the locations of pores.
doi:10.1371/journal.pone.0018715.g007
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reduce the ability of these cells to form appropriate junctional
complexes in monolayers [42]. On the other hand, over expression
of podocalyxin enhanced cell adhesion to fibronectin and P-
selectin [37,43]. In these cases integrins appeared to be intimately
involved in the podocalyxin dependent adhesion. This has led to
suggestions that the levels of podocalyxin expression may regulate
adhesion by influencing the distribution and activities of other
adhesion molecules on the cell surface [30]. Indeed the
extracellular domain of podocalyxin was demonstrated to be
necessary and sufficient to mediate cell microvillus formation
accompanied with actin cytoskeleton recruitment to the polarized
membrane region [44]. These observations are consistent with
suggestions that podocalyxin may mediate its effects through
interactions with other extracellular or membrane proteins.
Intracellularly, podocalyxin has been found to form complexes
with ezrin and to influence the activities of Rac1, MAPK, and
PI3K, increasing the metastatic potential of breast, kidney and
prostate cancers [36,45]. Our results indicate that podocalyxin
accumulates at the leading edge of migrating A549 cells in
association with arrays of filamentous actin. The silencing of
podocalyxin results in a loss of cell migration and a failure of the
cells to polarize. These cells are fully adherent to plastic and
extracellular matrix proteins suggesting that the loss in migration is
not related to an inability to interact with the vessel surface
(unpublished data XM, JAW).
The consistent detection of collagen type 1 in immunoprecip-
itates suggests that these two molecules are associated in some way.
It is unclear if this interaction is a direct one or if it is mediated
through other elements of a podocalyxin containing complex. As a
secretory type protein, collagen is major component of extracel-
lular matrix. We don’t know how much collagen was released to
extracellular environment during the TGF-b stimulation. To
examine the total collagen production, we used three different
Figure 8. Colocalization of collagen type 1 with podocalyxin. Double immunofluorescence was performed to determine the distribution of
podocalyxin (red) and collagen type 1 (green). A549 cells in chamber slide (A–D), A549 cells pretreated with TGF-b for 3 days were transferred into
transwells to establishing migration (E–G), and human breast cancer cell MDA-MB-231 in chamber slide (H–J) were fixed and permeablized for
following immunofluorescent staining. Rabbit anit-podocalyxin and goat anti-collagen type 1 chain 2 were visualized with Donkey anti-rabbit
conjugated with cy3 and Donkey anti-goat conjugated with Oregon green 488. The merged images were also shown respectively (C, G, J). A DIC
image (D) was also added to show the ruffle structure. The enrichments and colocalization of both podocalyxin and collagen were indicated by
arrows.
doi:10.1371/journal.pone.0018715.g008
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worked.
Integrins are obvious candidates of podocalyxin interacting
partners given the effects of antibodies to integrins on podocalyxin
dependent adhesion. Preliminary microscopic analysis indicated
that a1b1 integrin colocalized with podocalyxin on the leading
edge of membrane protrusions (data not shown). However efforts
to demonstrate collagen binding integrins such as a1b1 and a2b1
in podocalyxin immunoprecipitates were unsuccessful. While we
cannot exclude the possibility that integrins may be associated with
collagen-podocalyxin complexes but dissociated during the
immunoprecipitation procedure, so we have no data to support
such an interaction at this time. Our current data is more
consistent with integrin independent interaction of podocalyxin
and collagen type 1. However, the interactions between podoca-
lyxin and collagen may determine the distribution of integrins in
the processes of cell spreading and migration.
We believe that the demonstration of collagen type 1 on the
leading edges and termini of protrusions of migrating cells is a
novel observation. These collagen type 1 molecules were directly
secreted from cells rather than reorganized from extracellular
matrix. The images of migrating cells on transwell suggest that
newly synthesized collagen was transported to the cell surface and
focused to their protrusions. Collagen type1 is considered to be an
important inducer of EMT due to its ability to stimulate
E-cadherin adhesion complex disruption by induction of b-catenin
phosphorylation [30]. It has also been reported to control cell
membrane protrusion formation after remodeling by collagenase-1
on the leading edge of migratory vascular smooth muscle cell
[46,47]. Additionally, soluble collagen type 1 or peptides derived
from it have been reported to have chemotactic activities for
fibroblasts [48]. It is unclear how the interactions between collagen
and podocalyxin would contribute to cell migration.
In summary we have demonstrated that podocalyxin is up
regulated during TGF-b induced epithelial mesenchymal transi-
tion of A549 cells. Podocalyxin is required for cell migration as it
localizes to the leading edges of migrating cells and lowed
expression markedly impacts cell movement. Podocalyxin also
appears to be intimately associated with the regulation of E-
cadherin and vimentin that are involved in effective mesenchymal
transition. Another EMT feature, cytoskeleton assembly, was also
dependent on the production of podocalyxin. The interactions of
collagen and podocalyxin may be important in the development of
the invasive phenotype of cells following EMT.
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